New Clinical Trial at Archbold

Posted on

New Clinical Trial at Archbold

Wednesday, July 30, 2014

Clinical trials are medical studies that measure certain outcomes of procedures or medication in patients who volunteer to participate.  Often, these are nationwide studies, and in previous years, were mostly limited to large acute care medical centers and teaching hospitals.

Archbold Memorial Hospital’s Loudermilk Heart and Vascular Center has participated in numerous clinical trials since 2005, as well as the hospital’s Lewis Singletary Oncology Center since the introduction of their clinical trial program in 1990.

The Singletary Oncology Center is currently participating in several different trials that deal with a variety of cancers including breast, colon and lymphomas.  Most recently, the Center became a part of a trial that is testing a drug known as a PD-1 inhibitor and its effect on non-small cell lung cancer (NSCLC), which accounts for about 85% of all lung cancers.  The drug stimulates the patient’s own immune system to attack the cancer, and the drug is given to NSCLC patients whose cancer has progressed, despite the use of standard chemotherapy.  Archbold is one of only three sites in the state of Georgia hosting the trial.

“Because of our success with other trials, we were able to participate in this high-profile study,” said Teresa Coleman, MD, Medical and Clinical Trials Director at the Lewis Hall Singletary Oncology Center. “This new drug could potentially mean great things for patients who otherwise would have no other options.”

Trial participants do not have to be a current patient of the Singletary Oncology Center.  If a patient’s physician thinks the patient is a good candidate, they can refer the patient to the Center for further evaluation.

“One of our main goals is to let the public know that these options are available to them”, said Dr. Coleman.  “We recently had a patient referred to us from a well-known cancer research facility because they could not offer them the experimental therapeutic opportunity that we could.”

Dr. Coleman and her colleagues share a passion about clinical trial impact on patient care in the present and in the future. 

“Every study completed gives us knowledge we didn’t have before,” said Dr. Coleman. “Every participant—whether you’re a physician or patient—has an opportunity to change the world through medical research and clinical trials.”

“These studies potentially help thousands of patients worldwide. Archbold’s clinical trials program allows patients to have access to the latest medical advancements without having to leave Thomasville. We bring big city medicine to rural South Georgia, and we’re making a global impact from Thomasville.”